 |
|
The cutoff of transient elastography for the evaluation of portal hypertension should be different according to the etiology?
Beom Kyung Kim
Clin Mol Hepatol. 2021;27(1):91-93. Published online 2020 Dec 3 DOI: https://doi.org/10.3350/cmh.2020.0311
|
|
Citations to this article as recorded by
 Non-invasive tests-based risk stratification: Baveno VII and beyond
Georg Semmler, Mathias Jachs, Mattias Mandorfer
Clinical and Molecular Hepatology.2023; 29(1): 105. CrossRef Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey
Susana G Rodrigues
Clinical and Molecular Hepatology.2023; 29(1): 110. CrossRef The rise of non-invasive tools in the diagnosis of portal hypertension: Validation of the Baveno VII consensus
Jeong-Ju Yoo, Sang Gyune Kim
Clinical and Molecular Hepatology.2023; 29(1): 102. CrossRef Validation of non‐invasive diagnosis of CSPH in patients with compensated advanced chronic liver disease according to Baveno VII
Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik, Dong Hyun Sinn
Liver International.2023; 43(9): 1966. CrossRef Methods for assessing portal hypertension
S.M. Chooklin, S.S. Chuklin
EMERGENCY MEDICINE.2023; 19(6): 393. CrossRef Limited diagnostic value of liver stiffness for clinically significant portal hypertension in HBV-related cirrhosis
Mengmeng Zhang, Xiaoxia Niu, Di Zhao, Ruping Qi, Xuexin Qi, Jinghui Dong, Yuan Liu, Xu Bai, Qiang Yu, Changchun Liu, Jianming Cai
Abdominal Radiology.2022; 47(11): 3712. CrossRef
|